--- title: "Amneal Pharmaceuticals (AMRX) news: merger" url: "https://aibio.space/companies/amneal-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AMRX merger news: Amneal agrees to acquire Kashiv BioSciences for $375,000,000 in cash and 28,942,108 shares. Amneal Pharmaceuticals, Inc." --- AMRX Amneal Pharmaceuticals, Inc. NASDAQ · United States # Amneal Pharmaceuticals (AMRX) news AMRX merger news Debt Financing · 2026-08-03 ## [Amneal reprices $2.039 billion term loan and adds $45.2 million](https://aibio.space/news/amneal-reprices-2-039-billion-term-loan-adds-45-2-million/) Amneal's subsidiary converted $2.039 billion of term loans into new loans with a lower interest margin and added a $45.2 million term loan. The company estimates about $12 million of annual cash interest savings, and the maturity stays at August 1, 2032. ## Latest Amneal Pharmaceuticals news 1. 2026-04-22 Financings [Amneal agrees to acquire Kashiv BioSciences for $375,000,000 in cash and 28,942,108 shares](https://aibio.space/news/amneal-agrees-acquire-kashiv-biosciences-375-000-000-cash-28-942-108/) Amneal will pay $375 million in cash and issue 28,942,108 shares to buy Kashiv BioSciences, and some sellers are affiliates of the Amneal Group. Up to $350 million more depends on US regulatory milestones for Kashiv products. 2. 2026-02-03 Debt Financing [Amneal cuts term loan margin by 50 basis points, estimates $11 million annual interest savings](https://aibio.space/news/amneal-cuts-term-loan-margin-50-basis-points-estimates-11-million/) Amneal Pharmaceuticals LLC cut the interest margin on its term loans by 50 basis points in an amendment dated February 2, 2026, with JPMorgan Chase Bank, N.A. as administrative agent. The company estimates annual cash interest savings of about $11 million, and the loans still mature on August 1, 2032. ## Amneal Pharmaceuticals at a glance - **Ticker**: AMRX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $127.6 million ### Related companies - [Annexon](https://aibio.space/companies/annexon/) NASDAQ: ANNX - [Integrated BioPharma](https://aibio.space/companies/integrated-biopharma/) OTC: INBP - [PDS Biotechnology](https://aibio.space/companies/pds-biotechnology/) NASDAQ: PDSB - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) NASDAQ: BCAX - [IDEAYA Biosciences](https://aibio.space/companies/ideaya-biosciences/) NASDAQ: IDYA - [Scopus Biopharma](https://aibio.space/companies/scopus-biopharma/) OTC: SCPS - [Kiora Pharmaceuticals](https://aibio.space/companies/kiora-pharmaceuticals/) NASDAQ: KPRX - [Vyome Holdings](https://aibio.space/companies/vyome/) NASDAQ: HIND ### Also on NASDAQ - [Curanex Pharmaceuticals](https://aibio.space/companies/curanex-pharmaceuticals/) CURX - [INTELLIGENT BIO SOLUTIONS INC.](https://aibio.space/companies/intelligent-bio-solutions/) INBS - [Gilead Sciences](https://aibio.space/companies/gilead-sciences/) GILD - [Lumexa Imaging Holdings](https://aibio.space/companies/lumexa-imaging/) LMRI - [UTAH MEDICAL PRODUCTS INC](https://aibio.space/companies/utah-medical-products/) UTMD - [InMed Pharmaceuticals](https://aibio.space/companies/inmed-pharmaceuticals/) INM ## What Amneal Pharmaceuticals does Amneal Pharmaceuticals, Inc. is a diversified global biopharmaceutical company that develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes retail generics, injectables and biosimilars. Its Specialty segment offers branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Its AvKARE segment distributes pharmaceuticals and other products to the U.S. federal government, retail and institutional markets. The company operates principally in the United States, India and Ireland. CREXONT (carbidopa and levodopa extended release capsules) is indicated in the United States for Parkinson's disease, and IPX203 is licensed to Zambon Biotech S.A. for Europe and to Knight Therapeutics International S.A. for Canada and Latin America. Under a 15-year strategic collaboration with ApiJect Systems, Corp., Amneal is to install and operate manufacturing equipment leased from ApiJect for its blow fill seal delivery systems at its Brookhaven, New York facility. Amneal is also the preferred global supply partner for Metsera's weight loss medicines, and after Pfizer acquired Metsera, Pfizer shortened the term of that agreement. | Product or program | What it is | Stage | |---|---|---| | CREXONT | Carbidopa and levodopa extended release capsules for Parkinson's disease | marketed in the United States | | IPX203 | Carbidopa and levodopa product licensed for Europe, Canada and Latin America | not approved outside the United States | | ONGENTYS (opicapone) | Product licensed from BIAL-Portela for U.S. marketing and distribution | | | Metsera weight loss medicines | Supply partner arrangement with Metsera, Inc. | | Summarised from the company's [10-K filed Feb 27, 2026](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm). ## Amneal Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$3.02 billion](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/) | [$2.79 billion](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/) | | Research and development | [$186.2 million](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/) | [$190.7 million](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/) | | Net income (loss) | [$72.1 million](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/) | [-$116.9 million](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/) | | Cash from operations | [$340.0 million](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/) | [$295.1 million](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/) | | Cash and equivalents | [$282.0 million](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000031/) | [$110.6 million](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $127.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Amneal Pharmaceuticals Is Amneal Pharmaceuticals involved in a merger or acquisition? Our latest story on this, dated Apr 22, 2026: "Amneal agrees to acquire Kashiv BioSciences for $375,000,000 in cash and 28,942,108 shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/amneal-agrees-acquire-kashiv-biosciences-375-000-000-cash-28-942-108/). What is the ticker symbol of Amneal Pharmaceuticals? Amneal Pharmaceuticals, Inc. trades under the ticker AMRX on NASDAQ. Where is Amneal Pharmaceuticals listed? Amneal Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:2DT; LS:A2JLMD; LSX:A2JLMD. What is the SEC CIK of Amneal Pharmaceuticals? The SEC Central Index Key (CIK) for Amneal Pharmaceuticals, Inc. is 1723128. Its filings are on SEC EDGAR. How many shares does Amneal Pharmaceuticals have outstanding? 319,353,919 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Amneal Pharmaceuticals listed under? Our directory records Amneal Pharmaceuticals, Inc. under United States. What does Amneal Pharmaceuticals do? Our directory classifies Amneal Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Amneal Pharmaceuticals? The ISIN recorded for Amneal Pharmaceuticals, Inc. is US03168L1052. Does aibio.space cover Amneal Pharmaceuticals? aibio.space lists Amneal Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does Amneal Pharmaceuticals develop? Amneal Pharmaceuticals, Inc. is a diversified global biopharmaceutical company that develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes retail generics, injectables and biosimilars. What is CREXONT from Amneal Pharmaceuticals? CREXONT: Carbidopa and levodopa extended release capsules for Parkinson's disease Stage: marketed in the United States. What is IPX203 from Amneal Pharmaceuticals? IPX203: Carbidopa and levodopa product licensed for Europe, Canada and Latin America Stage: not approved outside the United States. What was Amneal Pharmaceuticals's revenue last year? $3.02 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Amneal Pharmaceuticals profitable? Amneal Pharmaceuticals, Inc. reported net income of $72.1 million for the fiscal year ended Dec 31, 2025, and generated $340.0 million of cash from operations, per its annual report to the SEC. How much does Amneal Pharmaceuticals spend on research and development? $186.2 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Amneal Pharmaceuticals Members talk about Amneal Pharmaceuticals (AMRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Amneal Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-08-10 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1723128/000114036126032014/ef20079825_ex99-1.htm) 2. 2026-04-22 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1723128/000119312526168231/d126526dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AMRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-AMRX/). ## SEC filings and registration - **SEC name**: Amneal Pharmaceuticals, Inc. - **CIK**: 1723128 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AMRX (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Phone**: (908) 947-3120 - **Shares outstanding**: 319,353,919 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: Atlas Holdings, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1723128/000114036126032014/ef20079825_8k.htm) filed 2026-08-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000031/amrx-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1723128/000162828026051900/amrx-20260803.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1723128/000114036126030491/ef20079129_8k.htm) filed 2026-07-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-20260730.htm) filed 2026-07-30 - [10-Q](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000020/amrx-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1723128/000162828026032137/amrx-20260506.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000019/amrx-20260507.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001723128), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Amneal Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AMRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Amneal Pharmaceuticals, Inc. - **Ticker**: AMRX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US03168L1052 - **Other listed symbols**: GETTEX:2DT; LS:A2JLMD; LSX:A2JLMD - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AMRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/amneal-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Amneal Pharmaceuticals (AMRX) news: merger", 2026-10-31, https://aibio.space/companies/amneal-pharmaceuticals/